#United States #Atlanta #UCB #Epilepsy #CDKL5

UCB's New Findings at the American Epilepsy Society Annual Meeting

UCB, a global leader in biopharmaceuticals, is making waves at the 2025 American Epilepsy Society (AES) Annual Meeting held from December 5-9 in Atlanta. The company will present 21 scientific abstracts detailing critical advancements, particularly focusing on epilepsy, which affects millions worldwide. Noteworthy among these is a Phase 3 study evaluating the efficacy and safety of FINTEPLA® (fenfluramine) in treating CDKL5 deficiency disorder (CDD).

Highlights of the Research

One of the key findings reported includes primary positive efficacy results from a Phase 3 trial of fenfluramine in CDKL5. This study demonstrates that patients receiving fenfluramine experienced a significantly greater reduction in seizure frequency compared to those on a placebo. It marks an important milestone since CDD is a debilitating condition linked to severe seizures. UCB emphasizes that, as of now, the safety and efficacy of this treatment for CDD have not been officially established or approved by any international regulatory authority, making ongoing clinical testing crucial.

In addition to addressing CDD, UCB will also present final results from a long-term open-label extension study of fenfluramine in patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The data gathered indicates a consistent safety profile, aligning with past Phase 3 studies of fenfluramine in these particular syndromes. Caregivers and investigators reported improvements in patient well-being and seizure management.

Understanding the Burden of Epilepsy

UCB aims to shed light on the day-to-day challenges faced by individuals living with epilepsy through findings from an interim caregiver survey. The data highlighted how disruptive seizures significantly affect daily functionalities and stress the need for holistic care solutions to support individuals and their families. UCB's Dimitrios Bourikas, Global Medical Head for DEE and Epilepsy, indicated the company's dedication to representing the voices of people living with epilepsy, underscoring their commitment to advancing epilepsy treatment and care.

The Risks of Prolonged Seizures

The presentation will touch on the critical insights from studies regarding prolonged seizures. Research shows that patients experiencing these episodes face heightened risks of serious complications, which can lead to life-threatening situations. The data emphasizes the urgency for immediate treatment options and highlights community preferences for rapid administration methods of acute seizure medications. Interviews conducted with patients and caregivers reveal a preference for medications that can be administered easily and offer quick relief, ideally within 1-2 minutes after seizure onset.

Moving Towards Better Outcomes

UCB's involvement in AES 2025 emphasizes the importance of continued research and discussions within the medical community to manage epilepsy effectively. Presentations include various aspects of treatment-related research, outlining their commitment to improving quality of life for those impacted by epilepsy. By sharing their findings and gathering insights from caregivers, UCB aspires to enhance communication and care strategies within the epilepsy community, fostering a future where individuals with epilepsy are supported and their conditions managed more effectively.

With a strong focus on innovation and research, UCB remains committed to its mission of transforming the lives of individuals living with severe diseases of the immune system or central nervous system. Interested parties can learn more about UCB's research and innovations at the UCB website or during the AES Annual Meeting.

For further inquiries, contact UCB at their U.S. Communications office or the Corporate Communications division for more details regarding the findings presented during the meeting.